Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Novabridge Biosciences (NBP) since 2026 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Novabridge Biosciences. Table 2 shows the detailed insider transactions. This company's CIK number is 1778016.
Total stock buying since 2026: $577,300.
Total stock sales since 2026: $147,124.
Total stock option exercises since 2026: $0.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2026 | 230,000 | $577,300 | 76,185 | $147,124 | 33,077 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2026-06 | 0 | $0 | 11,988 | $19,372 | 23,695 | $0 |
| 2026-05 | 0 | $0 | 64,197 | $127,752 | 9,382 | $0 |
| 2026-04 | 230,000 | $577,300 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2026-06-18 | Dennis Phillip Andrew (Chief Medical Officer) | Sale | 8,494 | .66 | 5,606 |
| 2026-06-17 | Dennis Phillip Andrew (Chief Medical Officer) | Option Ex | 23,695 | .00 | 0 |
| 2026-06-01 | Xu Cong Claire (SVP, Clinical Development) | Sale | 3,494 | 3.94 | 13,766 |
| 2026-05-30 | Xu Cong Claire (SVP, Clinical Development) | Option Ex | 9,382 | .00 | 0 |
| 2026-05-14 | Cao Sean Wuxiong (See Remarks) | Sale | 42,798 | 1.99 | 85,168 |
| 2026-04-24 | Hagler Mark Arnold (See Remarks) | Buy | 230,000 | 2.51 | 577,300 |
Insider trading activities including stock purchases, stock sales, and option exercises of NBP listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Novabridge Biosciences (symbol NBP, CIK number 1778016) see the Securities and Exchange Commission (SEC) website.